We observed that the Dox-treated groups (with Dox-induced CRTC1-MAML2 shRNA expression) had reduced tumor growth overtime with smaller tumors at the endpoints, as compared with the control groups (Figure 1, D and E). The gene discussed is CRTC1; the disease is neoplasm.